Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 18/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | LTK | P29376 | 1/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | PRKX | P51817 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411017 | 0.83 | DGAT1 (0.41) | EGLN2CLK4DGAT1 | |
| SCHEMBL3134115 | 0.74 | EGLN2 (0.45) | EGLN2 | |
| SCHEMBL9720035 | 0.74 | EGLN2 (0.45) | EGLN2 | |
| SCHEMBL22337954 | 0.74 | EGLN2 (0.49) | EGLN2 | |
| Formic Acid SCHEMBL30363762 | 0.74 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL22337956 | 0.71 | EGLN2 (0.42) | EGLN2 | |
| SCHEMBL7711671 | 0.70 | EGLN2 (0.53) | EGLN2 | |
| SCHEMBL21672416 | 0.69 | EGLN2 (0.41) | EGLN2DGAT1 | |
| SCHEMBL6568023 | 0.68 | FGFR1 (0.39) | NTRK1IGF1RFGFR1LTKMAP2K2 | |
| SCHEMBL23143440 | 0.68 | EGLN2 (0.64) | EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633756-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | Biogen Idec MA Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1618109-A2 | TRIAZOLO[1,5-C]PYRIMIDINES AND PYRAZOLO[1,5-C]PYRIMIDINES USEFUL AS A2A ADENOSINE RECEPTOR ANTAGONISTS | Biogen Idec MA Inc. (US) | 2006-01-25 | — | — | EP | claimed |
| WO-2004092173-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | claimed |
| WO-2004092172-A2 | TRIAZOLO[1,5-C]PYRIMIDINES AND PYRAZOLO[1,5-C]PYRIMIDINES USEFUL AS A2A ADENOSIN E RECEPTOR ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | claimed |
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250382300-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-18 | — | — | US | disclosed |
| EP-3883576-B1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12466831-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2025-11-11 | — | — | US | disclosed |
| US-12414952-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2025-09-16 | — | — | US | disclosed |
| CN-114466850-B | [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine | 拜耳股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-11629147-B2 | Triazolo-pyrimidine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-04-18 | — | — | US | disclosed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
| US-20140336994-A1 | STORAGE MEDIUM STORING IDENTIFYING PROGRAM, IDENTIFYING APPARATUS, AND IDENTIFYING METHOD | FUJITSU LIMITED (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2801921-A1 | Storage medium storing a program for the identification of a hybrid orbital of an atom, identifying apparatus and identifying method | FUJITSU LIMITED (JP) | 2014-11-12 | — | — | EP | disclosed |
| WO-2012129381-A1 | DEUTERATED PRELADENANT | CONCERT PHARMACEUTICALS INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| US-7834014-B2 | Parkinson's disease; [2-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)-octahydro-pyrido[1,2-a]pyrazin-7-yl]-methanol; | BIOGEN IDEC MA INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20070173505-A1 | A2a adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2007-07-26 | — | — | US | disclosed |
| US-20070010522-A1 | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2007-01-11 | — | — | US | disclosed |
| US-20020094935-A1 | N-([1,2,4] triazoloazinyl) thiophenesulfonamide compounds and their use as herbicides | DOW AGROSCIENCES LLC | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382300-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2B, ADORA2A, ADORA3 | EGLN2 2191/4885NTRK1 1681/4885IGF1R 1085/4885 |
| US-20070173505-A1 | A2a adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | EGLN2 3187/4885NTRK1 825/4885IGF1R 510/4885 |
| US-20020094935-A1 | N-([1,2,4] triazoloazinyl) thiophenesulfonamide compounds and their use as herbicides | PNPO, NAT1, DDT | EGLN2 2573/4885NTRK1 1234/4885IGF1R 2966/4885 |
| US-12466831-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | EGLN2 2086/4885NTRK1 1653/4885IGF1R 1093/4885 |
| US-11629147-B2 | Triazolo-pyrimidine compounds and uses thereof | ADORA2A, ADORA3, ADORA2B | EGLN2 3960/4885NTRK1 1340/4885IGF1R 907/4885 |
| US-20070010522-A1 | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists | ADORA2A, ADORA3, ADORA1 | EGLN2 4479/4885NTRK1 739/4885IGF1R 724/4885 |
| US-12414952-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2B, ADORA2A, ADORA3 | EGLN2 2019/4885NTRK1 1428/4885IGF1R 1000/4885 |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | EGLN2 159/4885NTRK1 1566/4885IGF1R 742/4885 |
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA1 | EGLN2 2410/4885NTRK1 1089/4885IGF1R 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.